Cargando…

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gozzetti, Alessandro, Bacchiarri, Francesca, Sammartano, Vincenzo, Defina, Marzia, Sicuranza, Anna, Mecacci, Bianca, Zappone, Elisabetta, Cencini, Emanuele, Fabbri, Alberto, Raspadori, Donatella, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783633/ https://www.ncbi.nlm.nih.gov/pubmed/33415072 http://dx.doi.org/10.3389/fonc.2020.570187

Ejemplares similares

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26(+) leukemia stem cells
por: Pacelli, Paola, et al.
Publicado: (2023)

Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
por: Cencini, Emanuele, et al.
Publicado: (2021)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
por: Gozzetti, Alessandro, et al.
Publicado: (2012)

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
por: Ippoliti, Micaela, et al.
Publicado: (2012)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI
por: Santoni, Adele, et al.
Publicado: (2022)

A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature
por: Bacchiarri, Francesca, et al.
Publicado: (2022)

Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
por: Sicuranza, Anna, et al.
Publicado: (2022)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients
por: Bocchia, Monica, et al.
Publicado: (2016)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Primary CNS lymphoma: latest updates and a 10-year monocenter experience
por: Cencini, Emanuele, et al.
Publicado: (2018)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Flow Cytometry Assessment of CD26(+) Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
por: Raspadori, Donatella, et al.
Publicado: (2019)

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers
por: Soefje, Scott A., et al.
Publicado: (2023)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
por: Liberatore, Carmine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b6vb4smuuukk9ktpes8atqfmuh